米氮平治疗青少年抑郁症的开放性研究

Open trial on efficacy of mirtazapine in adolescents with major depression

目的 探讨米氮平治疗青少年抑郁症的临床疗效和安全性。 方法 对32例符合《中国精神疾病分类方案与诊断标准》第3版(CCMD-3)抑郁症诊断标准的青少年患者进行为期8w的开放性米氮平治疗,以汉密尔顿抑郁量表(HAMD)和临床疗效总评量表(CGI)为评估临床疗效的工具。 结果31例患者全部完成研究,所用米氮平的平均剂量为28.8mg·d-1,在治疗结束时,HAMD和CGI得分较治疗前明显改善。副反应主要为过度镇静。 结论 米氮平治疗青少年抑郁症安全、有效。

Objective To understand the efficacy and safety of mirtazapine in adolescents with major depression. Method 32 adolescents who met diagnostic criteria for major depression in CCMD - 3 were treated with mirzatapine for 8 weeks, HAMD and CGI were used to assess clinical efficacy of rnirzatapine. Results 31 participants completed the trial, the average dosage of rnirzatapine was 28. 8mg/day. Scores of HAMD and CGI were significantly improved after treatment.; the main side reaction was excessive sedation Conclusion Mirzatapine is effective and safe agent for adolescents with major depression.